Compare LICN & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LICN | TVGN |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 21.3M |
| IPO Year | 2021 | 2021 |
| Metric | LICN | TVGN |
|---|---|---|
| Price | $1.23 | $6.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 45.9K | 6.7K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.14 |
| 52 Week High | $9.49 | $12.03 |
| Indicator | LICN | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 52.09 |
| Support Level | $1.03 | $6.22 |
| Resistance Level | $1.40 | $7.42 |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 16.74 | 67.29 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.